PRTODAY / NewswireToday Free press release distribution service network

More news: Research
Written by / Agency / Source: AREVA

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AREVA Med Roche Partnership - The Common Research Laboratory Aiming to Develop New Radio-immunotherapy Treatments for Cancer is Operational - As part of the partnership initiated in July 2012, Roche and AREVA Med, an AREVA subsidiary, have completed the construction of a common research laboratory located in France (Limousin Region) - Roche.com / AREVA.com
AREVA Med Roche Partnership - The Common Research Laboratory Aiming to Develop New Radio-immunotherapy Treatments for Cancer is Operational

 

NewswireToday - /newswire/ - Paris, Ile de France, France, 2013/09/20 - As part of the partnership initiated in July 2012, Roche and AREVA Med, an AREVA subsidiary, have completed the construction of a common research laboratory located in France (Limousin Region) - Roche.com / AREVA.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Operational since the spring of 2013, ARCoLab (AREVA Med Roche Common Laboratory) is dedicated to the development of alpha radio-immunotherapy (RIT alpha), an innovative and promising approach in the fight against cancer.

This ambitious research project brings together the expertise of the two partners: development of monoclonal antibodies targeting cancer cells and conducting clinical trials at Roche, and process engineering and isotope production of high-purity lead 212 at AREVA Med.

The anticipated underlying mechanism of action foresees an antibody to pre-target the cancer cells and to act as the anchoring location for the lead 212, a rare isotope currently at the heart of promising research in nuclear medicine. The short waves (alpha) generated by the lead 212 are supposed to locally destroy the cancer cells. This two-phased approach, which is far more targeted than traditional radiotherapy, is believed to avoid damaging the healthy cells.

ARCoLab is one the world’s leading nuclear medicine laboratories. Supported by the experts from both organisations, a joint team of five researchers and engineers from the Roche Institute of Research and Translational Medicine (IRRMT, part of Roche Pharma Research and Early Development) and AREVA Med currently evaluate the anti-tumor efficiency of the alpha RIT in different preclinical models. The first scientific results proving the mechanism of action are expected in 2014.

“If these results are conclusive, the alpha radio-immunotherapy technology may give birth, on the 2020 horizon, to a new generation of highly targeted anti-cancer treatments“, specified Corinne Le Goff, President of Roche Pharma France and the IRRMT. “We are proud of this scientific adventure taking place in France,” she added.

“The complimentary expertise of Roche and AREVA Med is simply remarkable. With this new common research laboratory, along with the expertise of our American subsidiary Macrocyclics, and Maurice Tubiana laboratory, AREVA Med has unrivalled competencies and means through which we hope for major advancements in the fight against cancer,” said Patrick Bourdet, CEO of AREVA Med.

The fight again cancer, a public health challenge and a priority for society
Cancer is responsible for one out of three deaths for men and one out of four for women. Since 1989, it has been the primary cause of death in France, ahead of cardiovascular diseases. Even if there has been undeniable progress made the past 15 years in terms of screening, diagnostics, and care (targeted therapies, personalised medicine), the medical needs and expectations of society remain very important.

However, to offer new chances to patients, it is essential to cooperate and develop competencies and talents. This is the shared vision of Roche and AREVA Med. In France, Roche founded in 2011 the first institute dedicated to partnership research, IRRMT. The Roche AREVA Med program could lead to the development of highly-targeted cancer treatments based on radio-immunotherapy, a technology which is today part of a growing number of preclinical and clinical research programs in France as well as the United States.

Contacts

Gisèle Calvache, Roche
T: +33 1 47 61 40 12 / +33 6 14 44 52 39
E: gisele.calvache[.]roche.com.

Sophie Matos, PrPa
T: +33 1 77 35 60 98 / +33 6 11 21 44 89
E: sophie.matos[.]prpa.fr.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AREVA

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


AREVA Med Roche Partnership - The Common Research Laboratory Aiming to Develop New Radio-immunotherapy Treatments for Cancer is Operational

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

AREVA | Roche
Publisher Contact: Katherine Berezowskyj - AREVA.com 
+33(0)1 34 96 12 15 press[.]areva.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AREVA securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AREVA / Company Profile


Read Research Most Recent Related Newswires:

DSM-Niaga Ready for Commercial Scale Production of 100%-recyclable Carpets
DSM Dyneema Introduces Whole New Level of Cut Protection with Black Dyneema® Diamond Technology
DSM Presents Sustainable and Healthy Dairy Solutions At FoodTech 2016
Frost & Sullivan Highlights GENEWIZ's Commitment to Providing Cutting-edge Services in the Life Science Research Services Market
DSM to Present its Latest Advances in Skin Biochemistry At IFSCC Conference
DSM Launches ForTii® Ace Next Generation High Performance Polyamides
DSM Launches New Cultures to Reduce Cheese Ripening Time
DSM Launches New 3C Technology to Reinvigorate Omega-3 Supplements Category
DSM to Highlight its Health and Indulgence Solutions for Baked Goods At IBIE
DSM Welcomes EU Novel Foods Approval for Heart Health Antioxidant
DSM Dyneema Successfully Defends Key Patent Against Competitor Challenge
DSM Expands its Automotive Electronics Portfolio with High-flow Akulon PA66
BD Expands Portfolio of Reproductive and Sexually Transmitted Infections Solutions
BD Announces New Software Release for Pyxis Enterprise Solution
DSM Opens its Asia Pacific Personal Care Technical & Application Center in Shanghai

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)